Generation Bio GBIO 深 滬
已收盤 02-06 16:00:00 美东时间
5.34
-0.400
-6.97%
華盛通- 最 高5.705
- 今 開5.70
- 成交量 55.19万股
- 最 低 5.34
- 昨 收 5.74
- 總市值 3598.38万
- 52周最高 7.516
- 市盈率 靜 --
- 換手率 8.19%
- 52周最低 3.004
- 委 比 99.90%
- 總股本 673.85万
- 歷史最高 557.20
- 量 比 4.52
- 振 幅 6.36%
- 歷史最低 3.004
- 每 手 1
- 風險率 1.01%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Takeda, XOMA ink new royalty agreement; amend existing deal
XOMA Royalty Corporation (XOMA) on Tuesday announced that it reached a new royalty sharing transaction with Takeda (TAK) and amended its existing royalty sharing agreement for the Japanese drugmaker’s...
2025-12-30 21:14
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
XOMA Royalty to acquire Generation Bio
XOMA Royalty (XOMA) has entered into an agreement to acquire Generation Bio (GBIO) for a cash price of $4.2913 per share. Generation Bio stockholders also will receive one non-transferable contingent ...
2025-12-16 06:28
XOMA Royalty To Acquire Generation Bio Co. For A Cash Price Of $4.2913 Per Share At The Closing Of The Merger
XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA), the biotech royalty aggregator, announced today it has entered into an agreement to acquire Generation Bio Co. ("Generation Bio") (NASDAQ:GBIO) for a cash price of
2025-12-16 06:02
XOMA Royalty Enters into Agreement to Acquire Generation Bio
<p>XOMA Royalty Corporation (XOMA Royalty) has agreed to acquire Generation Bio Co. (Generation Bio) for $4.2913 per share in cash. Generation Bio stockholders will also receive one non-transferable contingent value right (CVR) per share, entitling them to potential payments from net cash at closing, savings on lease obligations, proceeds from Generation Bio's license agreement with Moderna, and payments from out-licensing or selling Generation B...
2025-12-15 22:00
Generation Bio Announces Third Quarter 2025 Financial Results
Generation Bio Co reported its third quarter 2025 financial results. Cash stood at $89.6 million, down from $185.2 million in 2024. R&D expenses rose to $21.7 million, up from $15.1 million. G&A costs increased to $12.2 million from $9.2 million. Net loss narrowed to $5.5 million ($0.82 per share) from $15.3 million ($2.29 per share) in 2024. The company settled a lease dispute by paying $31 million and recorded a $25.5 million gain. Generation B...
2025-11-05 21:05
Generation Bio CEO Resignation and Leadership Transition
Generation Bio ( ($GBIO) ) has issued an update. On October 21, 2025, Generatio...
2025-10-23 04:29
Generation Bio President, CEO Geoff McDonough To Become Board Chair, Effective Oct. 31; Yalonda Howze Names Interim CEO, President
Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, today announced that Geoff McDonough, MD will step down as Chief
2025-10-23 04:09
2025 Q3生物制药裁员汇总
（来源：药研网） 金秋十月，凉风拂过，却未能带来行业期盼已久的复苏。 国外媒体Fierce Biotech 最新数据显示，刚过去的第三季度，共发生 62 起裁员...
2025-10-09 14:47
美股牛股 | Bullish上市首日飙升83%，手握2.4万枚比特币；大麻股Tilray涨超30%
加密货币交易所Bullish上市首日飙升83%，手握2.4万枚比特币；大麻股Tilray隔夜涨超30%，周内涨超90%，特朗普拟将大麻改为低危药物>>
2025-08-14 15:08
